AFT signs North American licensing deal for Pascomer topical treatment

AFT signs North American licensing deal for Pascomer topical treatment
Paul McBeth
By Paul McBeth July 5 (BusinessDesk) - AFT Pharmaceuticals is eyeing a US$10 million payment from a North America licensing deal but is keeping its earnings guidance unchanged for now.  The maker of Maxigesic painkillers reached the licensing and development agreement with US-based Timber Pharmaceuticals for its Pascomer drug, which treats skin lesions known as facial angiofibromas associated with the genetic disorder, tuberous sclerosis.  Timber will cover the cost of two clinical trials involving 120 patients, with the results due ne...

More Services

Creative solutions needed to keep NZ workers
Economy

Creative solutions needed to keep NZ workers

Robert Walters sees talent migration potentially getting worse in 2025.

‘Battle-hardened’ Trade Window eyes growth
Markets

‘Battle-hardened’ Trade Window eyes growth

The customs software minnow has weathered the storm. What next?

Pattrick Smellie 21 Nov 2024
Crimson big enough for ASX IPO: Beaton
Finance

Crimson big enough for ASX IPO: Beaton

A US market listing at a greater scale looks more likely.

Pattrick Smellie 06 Nov 2024
CoreLogic data suggests property market floor is nigh
Property

CoreLogic data suggests property market floor is nigh

Broad economic trends underpin the latest figures, CoreLogic's economist says.